AmorChem l.p., our fourth focused fund, was launched in 2011 to increase the commercial potential of the quality academic research carried out in Quebec.

With committed capital of $41.25M, AmorChem is focused on investing in promising life science projects originating from Québec-based universities and research centres.  AmorChem’s innovative business model involves financing research-stage projects to enable them to reach pre-clinical proof-of-concept in a semi-virtual mode.   AmorChem will generate returns through a two-pronged exit strategy:

		sell projects having reached early proof-of-concept to large biotechnology or pharmaceutical companies;
		or, bundle similar projects into new spin-out companies.

Projects are managed by AmorChem using a combination of the resources found in the researcher’s lab, other academic labs and contract research organisations.  In order to contribute efficiently to projects requiring small molecules, AmorChem established its own medicinal chemistry contract research organisation- NuChem Therapeutics Inc. In the case of antibodies, AmorChem formed an alliance with the NRC Biotechnology Research Institute.

We are actively seeking projects! Do you have a project that answers an unmet medical need? Is it scientifically innovative? Is it or can it be protected with IP? Would you like to go down a commercialisation path?

If YES, we'd like to hear from you!